bevacizumab + paclitaxel + trebananib

This is a combination regimen consisting of three agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, the process by which new blood vessels form to supply tumors. - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules and inhibits cell division, leading to apoptosis in rapidly dividing cancer cells. - **Trebananib** (AMG 386) is an investigational peptibody that blocks angiopoietin-1 and -2 from binding to the Tie2 receptor on endothelial cells, inhibiting non-VEGF-mediated angiogenesis. The combination has been studied primarily as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer and in ovarian cancer. Clinical trials have shown manageable toxicity but no significant improvement in progression-free survival when all three drugs are combined compared to other regimens[1][5]. Trebananib specifically targets alternative pathways of tumor blood vessel formation distinct from VEGF inhibition[5][6].

Other names

bevacizumab plus paclitaxel plus trebananib